Your account is not claimed yet. You can sign up with ORCID to claim your account.

Taku Fujimura (T Fujimura)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 57

Top Venues

The Journal of dermatology

Dermatologic therapy

Experimental dermatology

Cancers

Tohoku University Grduate School of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Tohoku University Grduate School of Medicine Sep 1o 2017

Japan

Lecturer :: Department of Dermatology

Publications

Taku Fujimura, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Koji Yoshino, Yasuhiro Fujisawa, Shoichiro Ishizuki, Kojiro Segawa, Jun Yamamoto, Akira Hashimoto, Yumi Kanbayashi, Yoshihide Asano
Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases. The Journal of dermatology (2023)
Kentaro Ohuchi, Tetsuya Ikawa, Ryo Amagai, Toshiya Takahashi, Yuna Roh, Junko Endo, Yumi Kambayashi, Yoshihide Asano, Taku Fujimura
LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated Macrophages. Cancers 15 (6) (2023)
Taku Fujimura, Koji Yoshino, Motoki Nakamura, Hiroshi Kato, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Shigeto Matsushita, Ryo Amagai, Emi Yamazaki, Manami Takahashi, Erika Tamabuchi, Akira Hashimoto, Yumi Kambayashi, Naoya Yamazaki, Toshio Miyata, Yoshihide Asano
Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol. Experimental dermatology (2023)
Yusuke Muto, Yumi Kanbayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Koji Yoshino, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, Ryo Amagai, Kentaro Ohuchi, Akira Hashimoto, Yoshihide Asano, Taku Fujimura
Adverse events associated with postoperative outcomes of adjuvant anti-PD-1 antibody therapy in both acral and non-acral cutaneous melanomas: A multicenter, observational, post hoc analysis study. The Journal of dermatology (2023)
Kentaro Ohuchi, Tetsuya Ikawa, Ryo Amagai, Toshiya Takahashi, Yuna Roh, Junko Endo, Yumi Kambayashi, Yoshihide Asano, Taku Fujimura
LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated Macrophages. Cancers 15 (6) (2023)
Rui Sasaki, Yoshihide Asano, Taku Fujimura
A pediatric case of corticosteroid-resistant erosive pustular dermatosis of scalp-like alopecia treated successfully with oral indomethacin, doxycycline, and topical tacrolimus. The Journal of dermatology 49 (9) (2022)
Kentaro Ohuchi, Ryo Amagai, Tetsuya Ikawa, Yusuke Muto, Yuna Roh, Junko Endo, Takeo Maekawa, Yumi Kambayashi, Yoshihide Asano, Taku Fujimura
Plasminogen activating inhibitor-1 promotes angiogenesis in cutaneous angiosarcomas. Experimental dermatology (2022)
Taku Fujimura, Sadanori Furudate, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Koji Yoshino, Akira Hashimoto, Yusuke Muto, Kentaro Ohuchi, Ryo Amagai, Yumi Kambayashi, Yasuhiro Fujisawa
Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy: A multicenter study of 90 Japanese cases. Skin health and disease 3 (1) (2022)
Taku Fujimura, Sadanori Furudate, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Koji Yoshino, Akira Hashimoto, Yusuke Muto, Kentaro Ohuchi, Ryo Amagai, Yumi Kambayashi, Yasuhiro Fujisawa
Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy: A multicenter study of 90 Japanese cases. Skin health and disease 3 (1) (2022)
Ryo Amagai, Yumi Kambayashi, Kentaro Ohuchi, Sadanori Furudate, Akira Hashimoto, Yoshihide Asano, Taku Fujimura
Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series. Dermatologic therapy 35 (11) (2022)
Kentaro Ohuchi, Ryo Amagai, Erika Tamabuchi, Yumi Kanbayashi, Taku Fujimura
Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy. The Journal of dermatology 49 (5) (2022)
Taku Fujimura
Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers. International journal of molecular sciences 23 (7) (2022)
Mayuko Amagai, Maki Ozawa, Ryo Amagai, Kentaro Ohuchi, Yusuke Muto, Yumi Kambayashi, Setsuya Aiba, Taku Fujimura
Nodal anaplastic large cell lymphoma with lymphomatoid papulosis following treatment of initially presumed atopic dermatitis with dupilumab: A case report. Dermatologic therapy 35 (3) (2021)
Toshihisa Hamada, Akimichi Morita, Hiraku Suga, Hikari Boki, Taku Fujimura, Yoji Hirai, Takatoshi Shimauchi, Chiharu Tateishi, Eiji Kiyohara, Ikko Muto, Hideki Nakajima, Riichiro Abe, Kazuyasu Fujii, Chikako Nishigori, Eiji Nakano, Kentaro Yonekura, Takeru Funakoshi, Masahiro Amano, Tomomitsu Miyagaki, Noriko Makita, Katsunori Manaka, Yoshihito Shimoyama, Makoto Sugaya
Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance. The Journal of dermatology (2021)
Erika Tamabuchi, Taku Fujimura, Chunbing Lyu, Setsuya Aiba
Phosphor-signal transducers and activator of transcription 1 signaling in mucosal lichen planus developing from metastatic bladder cancer treated with pembrolizumab. Dermatologic therapy 34 (4) (2021)
Takami Okuma, Sadanori Furudate, Yumi Kanbayashi, Akira Hashimoto, Setsuya Aiba, Taku Fujimura
Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy. The Journal of dermatology 48 (9) (2021)
Yusuke Muto, Taku Fujimura, Yumi Kanbayashi, Kentaro Ohuchi, Ryo Amagai, Takami Okuma, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba
Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma. The Journal of dermatology 48 (3) (2021)
Ryo Amagai, Taku Fujimura, Yusuke Muto, Yumi Kambayashi, Sadanori Furudate, Kentaro Ohuchi, Takami Okuma, Akira Hashimoto, Setsuya Aiba
Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma. Dermatologic therapy 34 (1) (2020)
Kentaro Ohuchi, Taku Fujimura, Chunbing Lyu, Ryo Amagai, Yusuke Muto, Setsuya Aiba
Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab. Dermatologic therapy 33 (6) (2020)
Taku Fujimura, Setsuya Aiba
Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers. Biomolecules 10 (8) (2020)
Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Yusuke Muto, Setsuya Aiba
Treatment of Advanced Melanoma: Past, Present and Future. Life (Basel, Switzerland) 10 (9) (2020)
Yoshihiro Ishida, Nobuyuki Kakiuchi, Kenichi Yoshida, Yoshikage Inoue, Hiroyuki Irie, Tatsuki R Kataoka, Masahiro Hirata, Takeru Funakoshi, Shigeto Matsushita, Hiroo Hata, Hiroshi Uchi, Yuki Yamamoto, Yasuhiro Fujisawa, Taku Fujimura, Ryunosuke Saiki, Kengo Takeuchi, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Atsushi Otsuka, Satoru Miyano, Kenji Kabashima, Seishi Ogawa
Unbiased Detection of Driver Mutations in Extramammary Paget Disease. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (6) (2020)
Yasuhiro Fujisawa, Taku Fujimura, S Matsushita, Y Yamamoto, H Uchi, A Otsuka, T Funakoshi, T Miyagi, H Hata, M Gosho, Y Kambayashi, M Aoki, T Yanagi, A Ohira, Yoshiyuki Nakamura, Takuya Maeda, K Yoshino
The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study. The British journal of dermatology 183 (5) (2020)
Ryo Amagai, Taku Fujimura, Yumi Kanbayashi, Yota Sato, Kayo Tanita, Kentaro Ohuchi, Akira Hashimoto, Setsuya Aiba
Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. The Journal of dermatology 47 (6) (2020)
Taku Fujimura, Yota Sato, Kayo Tanita, Ryo Amagai, Takatoshi Shimauchi, Dai Ogata, Satoshi Fukushima, Azusa Miyashita, Yasuhiro Fujisawa, Yumi Kanbayashi, Setsuya Aiba
Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. The Journal of dermatology 47 (6) (2020)
Yusuke Muto, Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Takami Okuma, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba
Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy. Dermatologic therapy 33 (6) (2020)
Kentaro Ohuchi, Taku Fujimura, Yumi Kambayashi, Ryo Amagai, Chunbing Lyu, Kayo Tanita, Yota Sato, Setsuya Aiba
Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment. Dermatologic therapy 33 (4) (2020)
Taku Fujimura, Koji Yoshino, Hiroshi Kato, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Yuki Yamamoto, Kayo Kunimoto, Takamichi Ito, Shigeto Matsushita, Takeo Maekawa, Kentaro Ohuchi, Ryo Amagai, Yusuke Muto, Sadanori Furudate, Yumi Kanbayashi, Akira Hashimoto, Setsuya Aiba
Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy. The Journal of dermatology 48 (3) (2020)
Feras M Ghazawi, Natsuko Iga, R Tanaka, Y Fujisawa, K Yoshino, Chisato Yamashita, Y Yamamoto, Taku Fujimura, Teruki Yanagi, H Hata, Shigeto Matsushita, M Le, Simon F Roy, F Lagacé, Yoshihiro Ishida, Kenji Kabashima, Atsushi Otsuka
Demographic and clinical characteristics of extramammary Paget's disease patients in Japan from 2000 to 2019. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (2) (2020)
Kentaro Ohuchi, Taku Fujimura, Chunbing Lyu, Ryo Amagai, Yusuke Muto, Setsuya Aiba
Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid. The Journal of dermatology 48 (3) (2020)
Erika Tamabuchi, Taku Fujimura, Chinbing Lyu, Setsuya Aiba
Multiple angiolymphoid hyperplasia with eosinophilia on the right arm showing unusual presentation. Dermatologic therapy 33 (6) (2020)
Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Yusuke Muto, Setsuya Aiba
Successful treatment of CCR4+ mycosis fungoides palmaris et plantaris with mogamulizumab monotherapy. Dermatologic therapy 33 (4) (2020)
Taku Fujimura, Yumi Kambayashi, Hisayuki Tono, Chinbing Lyu, Kentaro Ohuchi, Akira Hashimoto, Setsuya Aiba
Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy. Dermatologic therapy 33 (4) (2020)
Rui Sasaki, Taku Fujimura, Chunbing Lyu, Setsuya Aiba
Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin. The Journal of dermatology 47 (12) (2020)
Ryo Amagai, Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Akira Hashimoto, Setsuya Aiba
Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy. The Journal of dermatology 46 (5) (2019)
Yota Sato, Taku Fujimura, Masato Mizuashi, Setsuya Aiba
Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab. The Journal of dermatology 46 (10) (2019)
Taku Fujimura, K Tanita, Y Sato, C Lyu, Y Kambayashi, Y Fujisawa, H Uchi, Y Yamamoto, A Otsuka, K Yoshino, S Matsushita, T Funakoshi, S Fukushima, H Hata, A Hashimoto, S Aiba
Immune checkpoint inhibitor-induced vitiligo in advanced melanoma could be related to increased levels of CCL19. The British journal of dermatology 182 (5) (2019)
Yasuhiro Nakamura, Jun Asai, Hiroshi Igaki, Takashi Inozume, Kenjiro Namikawa, Ayato Hayashi, Satoshi Fukushima, Taku Fujimura, Takamichi Ito, Keisuke Imafuku, Ryota Tanaka, Yukiko Teramoto, Akane Minagawa, Takuya Miyagawa, Azusa Miyashita, Makoto Wada, Hiroshi Koga, Makoto Sugaya
Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019. The Journal of dermatology 47 (2) (2019)
Shino Ishihara-Yusa, Taku Fujimura, Chunbing Lyu, Masayuki Sugawara, Kazuhiro Sakamoto, Setsuya Aiba
Successful treatment of multiple eruptive adult xanthogranuloma concomitant with xanthelasma palpebrarum with probucol. The Journal of dermatology 46 (10) (2019)
Natsuko Iga, Atsushi Otsuka, Masahiro Hirata, Tatsuki R Kataoka, Hiroyuki Irie, Chisa Nakashima, Shigeto Matsushita, Hiroshi Uchi, Yuki Yamamoto, Takeru Funakoshi, Yasuhiro Fujisawa, Koji Yoshino, Taku Fujimura, Hiroo Hata, Yoshihiro Ishida, Kenji Kabashima
Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. Cancer science 110 (11) (2019)
Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Hisayuki Tono, Chunbing Lyu, Toshiya Takahashi, Akira Hashimoto, Setsuya Aiba
Successful treatment of unresectable recurrent programmed death ligand 1 moderately-expressing malignant melanoma of the nasal cavity with pembrolizumab monotherapy. The Journal of dermatology 46 (7) (2019)
Taku Fujimura, Yasuhiro Fujisawa, Yumi Kambayashi, Setsuya Aiba
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. Cancers 11 (9) (2019)
Moyuka Irimada, Taku Fujimura, Yumi Kambayashi, Akira Tsukada, Toshiya Takahashi, Akira Hashimoto, Setsuya Aiba
Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy. The Journal of dermatology 46 (7) (2019)
Taku Fujimura, Takahiro Okabe, Kayo Tanita, Yota Sato, Chunbing Lyu, Yumi Kambayashi, Shigenao Maruyama, Setsuya Aiba
A novel technique to diagnose non-melanoma skin cancer by thermal conductivity measurements: Correlations with cancer stromal factors. Experimental dermatology 28 (9) (2019)
Kana Takeda, Taku Fujimura, Kenichiro Tsuchiyama, Chunbing Lyu, Setsuya Aiba
Pembrolizumab resolves adult ashy dermatosis developing in patients with squamous cell carcinoma of the lung. The Journal of dermatology 46 (3) (2019)
Yota Sato, Taku Fujimura, Kayo Tanita, Lyu Chunbing, Shigeto Matsushita, Yasuhiro Fujisawa, Atsushi Otsuka, Yuki Yamamoto, Takanori Hidaka, Setsuya Aiba
Malassezia-derived aryl hydrocarbon receptor ligands enhance the CCL20/Th17/soluble CD163 pathogenic axis in extra-mammary Paget's disease. Experimental dermatology 28 (8) (2019)
Takahiro Haga, Taku Fujimura, Setsuya Aiba
Successful treatment of microcystic adnexal carcinoma on the philtrum with oral S-1 monotherapy. The Journal of dermatology 46 (6) (2019)
Taku Fujimura, Yumi Kambayashi, Kayo Tanita, Yota Sato, Takanori Hidaka, Astushi Otsuka, Hidenori Tanaka, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba
HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. The Journal of dermatology 45 (6) (2018)
Kayo Tanita, Taku Fujimura, Yota Sato, Chunbing Lyu, Setsuya Aiba
Minocycline decreases Th2 chemokines from M2 macrophages: Possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs. Experimental dermatology 27 (11) (2018)
Yota Sato, Taku Fujimura, Yumi Kambayashi, Kayo Tanita, Hisayuki Tono, Akira Hashimoto, Setsuya Aiba
Two cases of dabrafenib and trametinib therapy-failed advanced melanoma successfully controlled by nivolumab monotherapy. The Journal of dermatology 45 (9) (2018)
Taku Fujimura, Y Sato, Y Kambayashi, K Tanita, A Tsukada, H Terui, A Hashimoto, S Aiba
Three patients with advanced cutaneous angiosarcoma treated with eribulin: investigation of serum soluble CD163 and chemokine (C-X-C motif) ligand 10 as possible biomarkers predicting the biological behaviour of angiosarcoma. The British journal of dermatology 179 (6) (2018)
Taku Fujimura, Chinbing Lyu, Akira Tsukada, Yota Sato, Yumi Kambayashi, Setsuya Aiba
Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab. The Journal of dermatology 46 (5) (2018)
Taku Fujimura, Sadanori Furudate, Kayo Tanita, Yota Sato, Yumi Kambayashi, Takanori Hidaka, Setsuya Aiba
Successful treatment of relapsed folliculotropic mycosis fungoides with mogamulizumab followed by intensity-modulated radiotherapy. The Journal of dermatology 45 (4) (2017)
Taku Fujimura, Sadanori Furudate, Kayo Tanita, Yota Sato, Yumi Kambayashi, Takanori Hidaka, Setsuya Aiba
Successful control of phototherapy-resistant lymphomatoid papulosis with oral bexarotene. The Journal of dermatology 45 (2) (2017)
Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Yota Sato, Kayo Tanita, Akira Hashimoto, Setsuya Aiba
Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling. The Journal of dermatology 44 (9) (2017)
Taku Fujimura, Aya Kakizaki, Yumi Kambayashi, Yota Sato, Kayo Tanita, Chunbing Lyu, Sadanori Furudate, Setsuya Aiba
Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages. Experimental dermatology 27 (1) (2017)
Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Erika Tamabuchi, Eika Otake, Hisayuki Tono, Masato Mizuashi, Sadanori Furudate, Setsuya Aiba
Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab. The Journal of dermatology 45 (2) (2017)

Taku Fujimura.css-eqlu8i{font-size:small;padding-left:4px;} (T Fujimura)

Publication Activity (10 Years)

Top Topics

Top Venues

Taku Fujimura (T Fujimura)